Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a "humanized" transgenic mouse model of type 1 diabetes

Shahnawaz Imam, Raghavendra G. Mirmira, Juan C. Jaume

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Therapeutic options for treatment of type 1 diabetes (T1D) are still missing. New avenues for immune modulation need to be developed. Here we attempted at altering the diabetes outcome of our humanized model of T1D by inhibiting translation-initiation factor eIF5A hypusination in vivo. Double-transgenic (DQ8-GAD65) mice were immunized with adenoviral vectors carrying GAD65 for diabetes induction. Animals were subsequently treated with deoxyhypusine synthase (DHS) inhibitor GC7 and monitored for diabetes development over time. On one hand, helper CD4+ T cells were clearly affected by the downregulation of the eIF5A not just at the pancreas level but overall. On the other hand, the T regulatory cell component of CD4 responded with activation and proliferation significantly higher than in the non-GC7-treated controls. Female mice seemed to be more susceptible to these effects. All together, our results show for the first time that downregulation of eIF5A through inhibition of DHS altered the physiopathology and observed immune outcome of diabetes in an animal model that closely resembles human T1D. Although the development of diabetes could not be abrogated by DHS inhibition, the immunomodulatory capacity of this approach may supplement other interventions directed at increasing regulation of autoreactive T cells in T1D.

Original languageEnglish (US)
Pages (from-to)E791-E798
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume306
Issue number7
DOIs
StatePublished - Apr 1 2014

Fingerprint

Type 1 Diabetes Mellitus
Transgenic Mice
Down-Regulation
Peptide Initiation Factors
Cellular Structures
Helper-Inducer T-Lymphocytes
Pancreas
Animal Models
T-Lymphocytes
eukaryotic translation initiation factor 5A
deoxyhypusine synthase
Therapeutics

Keywords

  • Deoxyhypusine synthase
  • Mouse model
  • Type 1 diabetes physiopathology

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

@article{4c3078adeb164939a442e68eeffbcd73,
title = "Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a {"}humanized{"} transgenic mouse model of type 1 diabetes",
abstract = "Therapeutic options for treatment of type 1 diabetes (T1D) are still missing. New avenues for immune modulation need to be developed. Here we attempted at altering the diabetes outcome of our humanized model of T1D by inhibiting translation-initiation factor eIF5A hypusination in vivo. Double-transgenic (DQ8-GAD65) mice were immunized with adenoviral vectors carrying GAD65 for diabetes induction. Animals were subsequently treated with deoxyhypusine synthase (DHS) inhibitor GC7 and monitored for diabetes development over time. On one hand, helper CD4+ T cells were clearly affected by the downregulation of the eIF5A not just at the pancreas level but overall. On the other hand, the T regulatory cell component of CD4 responded with activation and proliferation significantly higher than in the non-GC7-treated controls. Female mice seemed to be more susceptible to these effects. All together, our results show for the first time that downregulation of eIF5A through inhibition of DHS altered the physiopathology and observed immune outcome of diabetes in an animal model that closely resembles human T1D. Although the development of diabetes could not be abrogated by DHS inhibition, the immunomodulatory capacity of this approach may supplement other interventions directed at increasing regulation of autoreactive T cells in T1D.",
keywords = "Deoxyhypusine synthase, Mouse model, Type 1 diabetes physiopathology",
author = "Shahnawaz Imam and Mirmira, {Raghavendra G.} and Jaume, {Juan C.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1152/ajpendo.00537.2013",
language = "English (US)",
volume = "306",
pages = "E791--E798",
journal = "American Journal of Physiology",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "7",

}

TY - JOUR

T1 - Eukaryotic translation initiation factor 5A inhibition alters physiopathology and immune responses in a "humanized" transgenic mouse model of type 1 diabetes

AU - Imam, Shahnawaz

AU - Mirmira, Raghavendra G.

AU - Jaume, Juan C.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Therapeutic options for treatment of type 1 diabetes (T1D) are still missing. New avenues for immune modulation need to be developed. Here we attempted at altering the diabetes outcome of our humanized model of T1D by inhibiting translation-initiation factor eIF5A hypusination in vivo. Double-transgenic (DQ8-GAD65) mice were immunized with adenoviral vectors carrying GAD65 for diabetes induction. Animals were subsequently treated with deoxyhypusine synthase (DHS) inhibitor GC7 and monitored for diabetes development over time. On one hand, helper CD4+ T cells were clearly affected by the downregulation of the eIF5A not just at the pancreas level but overall. On the other hand, the T regulatory cell component of CD4 responded with activation and proliferation significantly higher than in the non-GC7-treated controls. Female mice seemed to be more susceptible to these effects. All together, our results show for the first time that downregulation of eIF5A through inhibition of DHS altered the physiopathology and observed immune outcome of diabetes in an animal model that closely resembles human T1D. Although the development of diabetes could not be abrogated by DHS inhibition, the immunomodulatory capacity of this approach may supplement other interventions directed at increasing regulation of autoreactive T cells in T1D.

AB - Therapeutic options for treatment of type 1 diabetes (T1D) are still missing. New avenues for immune modulation need to be developed. Here we attempted at altering the diabetes outcome of our humanized model of T1D by inhibiting translation-initiation factor eIF5A hypusination in vivo. Double-transgenic (DQ8-GAD65) mice were immunized with adenoviral vectors carrying GAD65 for diabetes induction. Animals were subsequently treated with deoxyhypusine synthase (DHS) inhibitor GC7 and monitored for diabetes development over time. On one hand, helper CD4+ T cells were clearly affected by the downregulation of the eIF5A not just at the pancreas level but overall. On the other hand, the T regulatory cell component of CD4 responded with activation and proliferation significantly higher than in the non-GC7-treated controls. Female mice seemed to be more susceptible to these effects. All together, our results show for the first time that downregulation of eIF5A through inhibition of DHS altered the physiopathology and observed immune outcome of diabetes in an animal model that closely resembles human T1D. Although the development of diabetes could not be abrogated by DHS inhibition, the immunomodulatory capacity of this approach may supplement other interventions directed at increasing regulation of autoreactive T cells in T1D.

KW - Deoxyhypusine synthase

KW - Mouse model

KW - Type 1 diabetes physiopathology

UR - http://www.scopus.com/inward/record.url?scp=84900541452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900541452&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00537.2013

DO - 10.1152/ajpendo.00537.2013

M3 - Article

C2 - 24496311

AN - SCOPUS:84900541452

VL - 306

SP - E791-E798

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 0193-1849

IS - 7

ER -